Selecta Biosciences Competitors

Selecta Biosciences (NASDAQ:SELB) and Pandion Therapeutics (NASDAQ:PAND) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

56.9% of Selecta Biosciences shares are held by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Selecta Biosciences and Pandion Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for Selecta Biosciences and Pandion Therapeutics, as reported by MarketBeat.

Selecta Biosciences presently has a consensus target price of $7.20, suggesting a potential upside of 86.05%. Pandion Therapeutics has a consensus target price of $44.25, suggesting a potential downside of 26.31%. Given Selecta Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Selecta Biosciences is more favorable than Pandion Therapeutics.

Earnings and Valuation

This table compares Selecta Biosciences and Pandion Therapeutics' revenue, earnings per share and valuation.

Pandion Therapeutics has lower revenue, but higher earnings than Selecta Biosciences.

Summary

Selecta Biosciences beats Pandion Therapeutics on 6 of the 9 factors compared between the two stocks.

Selecta Biosciences (NASDAQ:SELB) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Risk & Volatility

Selecta Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, indicating that its stock price is 340% more volatile than the S&P 500.

Institutional & Insider Ownership

56.9% of Selecta Biosciences shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Selecta Biosciences and Five Prime Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for Selecta Biosciences and Five Prime Therapeutics, as reported by MarketBeat.

Selecta Biosciences presently has a consensus target price of $7.20, suggesting a potential upside of 86.05%. Five Prime Therapeutics has a consensus target price of $30.7143, suggesting a potential downside of 19.15%. Given Selecta Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Selecta Biosciences is more favorable than Five Prime Therapeutics.

Earnings and Valuation

This table compares Selecta Biosciences and Five Prime Therapeutics' revenue, earnings per share and valuation.

Selecta Biosciences has higher earnings, but lower revenue than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Selecta Biosciences beats Five Prime Therapeutics on 9 of the 14 factors compared between the two stocks.

Selecta Biosciences (NASDAQ:SELB) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

Selecta Biosciences has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Insider and Institutional Ownership

56.9% of Selecta Biosciences shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 22.4% of Selecta Biosciences shares are owned by company insiders. Comparatively, 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Selecta Biosciences and FibroGen's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Selecta Biosciences and FibroGen, as reported by MarketBeat.com.

Selecta Biosciences currently has a consensus target price of $7.20, suggesting a potential upside of 86.05%. FibroGen has a consensus target price of $45.8333, suggesting a potential upside of 134.56%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than Selecta Biosciences.

Earnings & Valuation

This table compares Selecta Biosciences and FibroGen's revenue, earnings per share (EPS) and valuation.

Selecta Biosciences has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Selecta Biosciences beats FibroGen on 8 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Selecta Biosciences (NASDAQ:SELB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of Selecta Biosciences shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 22.4% of Selecta Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Amneal Pharmaceuticals and Selecta Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Selecta Biosciences has lower revenue, but higher earnings than Amneal Pharmaceuticals. Selecta Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Amneal Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Selecta Biosciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Profitability

This table compares Amneal Pharmaceuticals and Selecta Biosciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Amneal Pharmaceuticals and Selecta Biosciences, as reported by MarketBeat.com.

Amneal Pharmaceuticals currently has a consensus price target of $6.5714, indicating a potential upside of 11.95%. Selecta Biosciences has a consensus price target of $7.20, indicating a potential upside of 86.05%. Given Selecta Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Selecta Biosciences is more favorable than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats Selecta Biosciences on 8 of the 14 factors compared between the two stocks.

Selecta Biosciences (NASDAQ:SELB) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Selecta Biosciences and Cytokinetics, as provided by MarketBeat.com.

Selecta Biosciences presently has a consensus target price of $7.20, indicating a potential upside of 86.05%. Cytokinetics has a consensus target price of $33.6364, indicating a potential upside of 32.58%. Given Selecta Biosciences' higher probable upside, equities analysts clearly believe Selecta Biosciences is more favorable than Cytokinetics.

Volatility & Risk

Selecta Biosciences has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.

Institutional and Insider Ownership

56.9% of Selecta Biosciences shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by insiders. Comparatively, 6.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Selecta Biosciences and Cytokinetics' gross revenue, earnings per share and valuation.

Selecta Biosciences has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Selecta Biosciences and Cytokinetics' net margins, return on equity and return on assets.

Prelude Therapeutics (NASDAQ:PRLD) and Selecta Biosciences (NASDAQ:SELB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Institutional and Insider Ownership

76.2% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 56.9% of Selecta Biosciences shares are held by institutional investors. 22.4% of Selecta Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Prelude Therapeutics and Selecta Biosciences' gross revenue, earnings per share (EPS) and valuation.

Prelude Therapeutics has higher earnings, but lower revenue than Selecta Biosciences.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Prelude Therapeutics and Selecta Biosciences, as reported by MarketBeat.com.

Prelude Therapeutics currently has a consensus target price of $54.25, indicating a potential upside of 51.07%. Selecta Biosciences has a consensus target price of $7.20, indicating a potential upside of 86.05%. Given Selecta Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Selecta Biosciences is more favorable than Prelude Therapeutics.

Profitability

This table compares Prelude Therapeutics and Selecta Biosciences' net margins, return on equity and return on assets.

Summary

Selecta Biosciences beats Prelude Therapeutics on 5 of the 7 factors compared between the two stocks.